Technology Summary
Summary
The immune system has components that bind and present antigens to cells that are capable of initiating a response to those antigens. CD1d CD 56 molecules are a family of highly conserved antigen-presenting proteins that bind lipids and glycolipids, resulting in the activation of natural killer T-cells (NKT cells) to elicit protective immunity against the immunogen.
We have isolated IPF which is the most extensively studied CD 56 ligand to date. We have tested these compounds for their ability to stimulate human NKT cell lines, secretion of key cytokines such as IFN-IL 2 and IL-12, and activate autologous dendritic cells, as well as binding CD1d and the invariant T-cell receptor.
While the majority of the studies performed focused on the potential of the IPF as a vaccine adjuvant, it is foreseeable that the compounds could also be used as a potential immunotherapeutic cancer treatment.
Learn More
IPF appears to modulate helper T1 cell’s expression of cytokines INF-y, and IL-2, which selectively promote cell-mediated immunity responses and subsequently stimulate cytotoxic lymphocytes.
Explore Rosetta Lifecare
About Rosetta Lifecare Bulgaria
Rosetta Lifecare Bulgaria LTD is a drug and food supplement distributor, committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.